Skip to content
Inciteful Med

Symptoms, Progression, and the 'Plus' Syndrome

Last updated:

Autosomal Dominant Optic Atrophy (ADOA) causes gradual, painless central vision loss and blue-yellow color vision changes starting in childhood. About 20-30% of patients develop ADOA Plus syndrome, causing additional symptoms like hearing loss, muscle weakness, and balance issues.

Key Takeaways

  • • ADOA primarily causes gradual, painless central vision loss and blue-yellow color vision changes that affect both eyes.
  • • Visual symptoms typically begin in early childhood between the ages of 4 and 6, though the exact onset can vary widely.
  • • About 20% to 30% of patients develop ADOA Plus syndrome, which involves symptoms outside the eyes.
  • • Hearing loss, muscle weakness, neuropathy, and balance issues are the most common non-visual symptoms in ADOA Plus.
  • • The specific type of OPA1 gene mutation you have strongly influences your risk for developing ADOA Plus syndrome.

While every person’s experience with Autosomal Dominant Optic Atrophy (ADOA) is unique, the condition typically follows a predictable pattern of symptoms. Understanding these patterns—and knowing when the condition might involve more than just your eyes—can help you manage your health with confidence.

Classic Visual Symptoms

ADOA primarily affects central vision, which is the “high-definition” vision you use for reading, driving, and recognizing faces [1]. Because it is a hereditary condition, it almost always affects both eyes (bilateral) at a similar rate [2][3].

Key symptoms include:

  • Gradual, Painless Vision Loss: The decline is usually slow and does not cause physical pain [3][4].
  • Central Scotomas: These are “blind spots” or areas of blurred vision in the center or just off-center of your visual field [1][4].
  • Color Vision Changes: A hallmark sign of ADOA is a specific difficulty distinguishing between blues and yellows, a condition known as blue-yellow dyschromatopsia [5][6].
  • Optic Disc Pallor: During an eye exam, a doctor may notice the optic nerve looks pale. This “pallor” indicates that some of the nerve fibers have thinned [7][2].

Timing and Age of Onset

While the cellular changes associated with ADOA may be present from birth, noticeable symptoms typically appear in early childhood [8]. The average age of onset is around 4 to 6 years old, though many patients are not diagnosed until they begin school and have difficulty seeing the board [9][10].

However, the “clock” for ADOA is highly variable. Some individuals may not notice visual changes until their teenage years or even into middle adulthood [8][11]. This variation often depends on the specific genetic mutation and environmental factors [12].

Understanding ADOA “Plus” Syndrome

For about 20% to 30% of patients, ADOA involves symptoms that go beyond the eyes [11][7]. This is referred to as ADOA Plus syndrome. It occurs because the mitochondria—the “powerhouses” affected by the condition—are found in cells throughout your entire body, not just the optic nerve [13].

Common “Plus” symptoms include:

  • Hearing Loss (Hypoacusis): This is the most frequent extraocular (outside the eye) symptom [14][11].
  • Muscle Weakness (Myopathy): Some patients experience fatigue or weakness in their muscles [7].
  • Balance Issues (Ataxia): This can manifest as clumsiness or difficulty with coordination [7].
  • Neuropathy: Tingling, numbness, or “pins and needles” in the hands or feet [11].

Why Does “Plus” Happen?

Whether a person develops classic ADOA or ADOA Plus often depends on the specific type and location of the mutation within the OPA1 gene [7]. For example, “missense” mutations (where a single DNA building block is swapped) can sometimes cause a more severe “dominant-negative” effect on the cell’s machinery, which is more likely to lead to the “Plus” phenotype compared to mutations that simply reduce the amount of protein produced [15][7]. Identifying your specific mutation through genetic testing is the best way to understand your personal risk for these extra symptoms.

Frequently Asked Questions

What are the first signs of Autosomal Dominant Optic Atrophy?
The most common early signs are gradual, painless central vision loss and difficulty distinguishing between blue and yellow colors. These visual changes typically appear in early childhood, often around ages 4 to 6, and affect both eyes similarly.
What is ADOA Plus syndrome?
ADOA Plus syndrome occurs in about 20% to 30% of patients when the condition affects areas of the body beyond the eyes. This happens because the underlying mitochondrial dysfunction can also impact hearing, muscles, and nerves.
Does ADOA cause hearing loss?
Yes, hearing loss is the most common symptom outside of the eyes for people who develop ADOA Plus syndrome. If you have ADOA, your doctor may recommend a baseline hearing test to check for early signs of hearing decline.
How do I know if I will develop ADOA Plus syndrome?
Your risk for developing ADOA Plus often depends on your specific type of OPA1 gene mutation. Genetic testing can identify your exact mutation, helping your doctor determine if you have a higher risk for extra symptoms like muscle weakness or balance issues.
What is a central scotoma?
A central scotoma is a blind spot or area of blurred vision that occurs in the center or just off-center of your visual field. In ADOA, this happens due to the thinning of nerve fibers in the optic nerve, which your doctor may observe as optic disc pallor.

Questions for Your Doctor

  • • Does my specific OPA1 mutation (genotype) put me at a higher risk for ADOA Plus syndrome?
  • • Should I have a baseline hearing test (audiometry) to check for early signs of hypoacusis?
  • • Are the balance or muscle issues I am experiencing related to my ADOA, and should I see a neurologist?
  • • How frequently should we monitor my visual fields to check for changes in my blind spots (scotomas)?
  • • Given that I have ADOA, are there specific screenings my children or siblings should undergo, even if they don't have symptoms yet?

Questions for You

  • • Have I noticed any difficulty hearing in crowded rooms or trouble following conversations?
  • • Do I ever feel unexpectedly clumsy, or have I noticed changes in my balance or muscle strength?
  • • When I look at colors, do blues and yellows seem less vibrant or harder to distinguish than they used to?
  • • Does my vision loss feel equal in both eyes, or is one eye significantly different from the other?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    New avenues for therapy in mitochondrial optic neuropathies.

    Ng WSV, Trigano M, Freeman T, et al.

    Therapeutic advances in rare disease 2021; (2()):26330040211029037 doi:10.1177/26330040211029037.

    PMID: 37181108
  2. 2

    IT TAKES TWO TO TANGO: potential novel therapies for autosomal dominant optic atrophy.

    Sampige R, Seaborn LEA, Pluenneke M, et al.

    Frontiers in ophthalmology 2025; (5()):1688232 doi:10.3389/fopht.2025.1688232.

    PMID: 41268195
  3. 3

    The crossroads of Leber hereditary optic neuropathy and autosomal dominant optic Atrophy: Clinical profiles of patients with coexisting pathogenic genetic variants.

    Halawani MA, Badeeb NO

    American journal of ophthalmology case reports 2025; (38()):102346 doi:10.1016/j.ajoc.2025.102346.

    PMID: 40417638
  4. 4

    Clinical and Structural Parameters in Autosomal Dominant Optic Atrophy Patients: A Cross-Sectional Study Using Optical Coherence Tomography.

    Camós-Carreras A, Figueras-Roca M, Albà-Arbalat S, et al.

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2024; (45(3)):273-277 doi:10.1097/WNO.0000000000002294.

    PMID: 39805076
  5. 5

    [Hereditary Optic Neuropathies].

    Rüther K

    Klinische Monatsblatter fur Augenheilkunde 2018; (235(6)):747-763 doi:10.1055/a-0583-6290.

    PMID: 29490390
  6. 6

    Short Wavelength Automated Perimetry, Standard Automated Perimetry, and Optical Coherence Tomography in Dominant Optic Atrophy.

    Lombardo M, Cusumano A, Mancino R, et al.

    Journal of clinical medicine 2024; (13(7)) doi:10.3390/jcm13071971.

    PMID: 38610740
  7. 7

    Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy.

    Ham M, Han J, Osann K, et al.

    Mitochondrion 2019; (46()):262-269 doi:10.1016/j.mito.2018.07.006.

    PMID: 30165240
  8. 8

    A Perspective on Accelerated Aging Caused by the Genetic Deficiency of the Metabolic Protein, OPA1.

    Erchova I, Sun S, Votruba M

    Frontiers in neurology 2021; (12()):641259 doi:10.3389/fneur.2021.641259.

    PMID: 33927681
  9. 9

    Comparison of the clinical and genetic features of autosomal dominant optic atrophy and normal tension glaucoma in young Chinese adults.

    Zhang Y, Sun X, Tian G, Chen Y

    Eye (London, England) 2023; (37(4)):624-630 doi:10.1038/s41433-022-01990-y.

    PMID: 35273349
  10. 10

    Autosomal dominant optic atrophy caused by six novel pathogenic OPA1 variants and genotype-phenotype correlation analysis.

    Han J, Li Y, You Y, et al.

    BMC ophthalmology 2022; (22(1)):322 doi:10.1186/s12886-022-02546-0.

    PMID: 35883160
  11. 11

    A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family.

    Ahmad KE, Davis RL, Sue CM

    Journal of neurology 2015; (262(10)):2323-8 doi:10.1007/s00415-015-7849-6.

    PMID: 26194196
  12. 12

    Visual Function and Inner Retinal Structure in Relation to Birth Factors in Autosomal Dominant Optic Atrophy.

    Eckmann-Hansen C, Bek T, Sander B, Larsen M

    Investigative ophthalmology & visual science 2023; (64(10)):32 doi:10.1167/iovs.64.10.32.

    PMID: 37498569
  13. 13

    Targeting DRP1 with Mdivi-1 to correct mitochondrial abnormalities in ADOA+ syndrome.

    Lin Y, Wang D, Li B, et al.

    JCI insight 2024; (9(15)).

    PMID: 38916953
  14. 14

    Autosomal dominant optic atrophy plus due to the novel OPA1 variant c.1463G>C.

    Finsterer J, Laccone F

    Metabolic brain disease 2019; (34(4)):1023-1027 doi:10.1007/s11011-019-00425-0.

    PMID: 31152339
  15. 15

    Contrasting pathophysiological mechanisms of OPA1 mutations in autosomal dominant optic atrophy.

    Yao SQ, Liang JJ, Zhou H, et al.

    Cell death discovery 2025; (11(1)):259 doi:10.1038/s41420-025-02442-8.

    PMID: 40447565

This page provides educational information about ADOA symptoms and ADOA Plus syndrome. Always consult your ophthalmologist or neurologist for a personal medical evaluation and genetic counseling.

Stay up to date

Get notified when new research about Autosomal dominant optic atrophy is published.

No spam. Unsubscribe anytime.